For the quarter ending 2025-12-31, NEUP had $8,521,859 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 1,864,092 | -9,906,504 | -369,632 |
| Share-based compensation | 93,701 | 111,277 | 163,772 |
| Depreciation and amortization expense | 165,789 | 165,792 | 662,890 |
| Non-cash rent expense | -87,269 | -27,393 | -114,363 |
| Change in fair value of accompanying warrant liability | -5,379,434 | 4,390,726 | -956,340 |
| Change in fair value of contingent consideration | -5,975 | -12,763 | 716,654 |
| Effect of foreign currency remeasurement | -224,289 | -32,644 | -242,348 |
| Accounts receivable, non-trade | 1,108,150 | -10,190 | -114,936 |
| Prepaid expenses | - | - | 453,058 |
| Prepaid insurance expense | -195,365 | -517,874 | - |
| Accounts payable | -850,019 | 216,359 | -917,663 |
| Accrued expenses and other current liabilities | -1,602,739 | 718,261 | 1,486,656 |
| Operating lease liabilities | -85,210 | -31,104 | -123,304 |
| Deferred tax liability | -34,793 | -34,793 | -468,427 |
| Contingent consideration | - | - | -133,080 |
| Other non-current liabilities | - | - | -2,886 |
| Net cash used in operating activities | -6,435,815 | -3,794,648 | 77,229 |
| Proceeds from the sale of equity, net of issuance costs | 14,662,268 | 3,253,615 | 1,528,276 |
| Net cash provided by (used in) financing activities | 14,662,268 | 3,253,615 | 1,528,276 |
| Effect of exchange rate on changes on cash, cash equivalents, and restricted cash | 295,406 | -19,455 | -3,750 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 8,521,859 | -560,488 | 1,601,755 |
| Cash and cash equivalents at beginning of period | 13,728,202 | 14,288,690 | 12,686,935 |
| Cash and cash equivalents at end of period | 22,250,061 | 13,728,202 | 14,288,690 |
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)